AsthmaChildren aged 6-17 could benefit from tiotropium Respimat if the drug is added to maintenance asthma therapy, according to findings from a Phase 3 clinical trial.

The findings, presented at the European Respiratory Society’s (ERS) 2016’s annual conference, were taken from the Phase 3 CanoTinA-asthma trail by pharma Boehringer Ingelheim.

The study found that by adding tiotropium Respimat to maintenance therapy lung function was significantly improved when compared to placebo. The trial investigated tiotropium Respimat as an add-on therapy for children who were already taking an inhaled corticosteroid (ICS), or an ICS combined with other maintenance therapy. In the study, the safety and tolerability of tiotropium Respimat were shown to be comparable to placebo. 

A further pooled analysis from four studies – VivaTinA-asthma, RubaTinA-asthma, PensieTinA-asthma and CanoTinA-asthma – also presented at the ERS conference, showed that adding tiotropium Respimat to maintenance therapy for children aged 6-17 years has a comparable safety profile to placebo, while also showing that tiotropium Respimat “significantly” improved peak expiratory flow, a common measure of asthma control. 

Additionally, a new post-hoc analysis of the NinoTinA-asthma trial showed the safety profile of adding tiotropium Respimat to maintenance therapy is consistent with that found in older children and adults.

Boehringer Ingelheim also presented further abstracts at ERS, including:

  • New long-term data from the INPULSIS and INPULSIS-ON1 trials demonstrated the continued safety and beneficial effect of nintedanib (OFEV) for patients with idiopathic pulmonary fibrosis. The findings revealed that long-term treatment up to 51 months had a manageable safety and tolerability profile, with no new safety signals identified. It was also found that nintedanib slows disease progression regardless of baseline physiologic impairment as measured by several pulmonary function tests. For more information click here.
  • The use of tiotropium+olodaterol Respimat, with exercise training and behaviour modification, significantly increased exercise capacity of people living with COPD compared to placebo. The PHYSACTO trial data also showed improvements in shortness of breath associated with physical activity for people. For more information click here.